Annovis Bio (ANVS)
NYSE:ANVS
Want to see ANVS full AI Analyst Report?
ANVS Stock Chart & Stats
$1.87
-$0.04(-0.79%)
At close: 4:00 PM EST
$1.87
-$0.04(-0.79%)
Day’s Range― - ―
52-Week Range$1.36 - $5.50
Previous CloseN/A
Volume368.97K
Average Volume (3M)932.14K
Market Cap
$63.54M
Enterprise Value-$19.50B
Total Cash (Recent Filing)$19.53B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.64
Next Earnings
May 19, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding34,532,394
10 Day Avg. Volume1,873,276
30 Day Avg. Volume932,137
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-306.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda660.37
Forecast
1Y Price Target
$12.50Price Target Upside568.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Progress And SafetySubstantial patient enrollment in the pivotal Alzheimer's Phase 3 trial, together with an independent safety review reporting no concerns, supports continued study momentum and investor confidence in trial conduct.
Efficacy Signals And Regulatory PotentialEarly efficacy signals and biomarker improvements observed in Alzheimer's and Parkinson's studies could underpin an initial regulatory filing and eventual label expansion if confirmed by pivotal results.
Financing / CapitalizationA financing extended the company's cash runway beyond the key Phase 3 data milestone for buntanetap, reducing funding pressure and supporting continued trial execution.
Bears Say
Clinical Timeline UncertaintyA revised timeline for the symptomatic readout delays availability of efficacy data, prolonging uncertainty for investors and extending the timeframe before potential regulatory decisions.
Financial Position And Dilution RiskA substantial operating loss and limited cash reserves indicate a likely need to raise additional capital to fund ongoing trials, creating potential dilution risk for existing shareholders.
Regulatory And Development RiskAlzheimer's disease is a high-risk therapeutic area, increasing development and regulatory uncertainty and amplifying the risk that trial outcomes may not lead to approval.
Annovis Bio News
ANVS FAQ
What was Annovis Bio’s price range in the past 12 months?
Annovis Bio lowest stock price was $1.35 and its highest was $5.50 in the past 12 months.
What is Annovis Bio’s market cap?
Annovis Bio’s market cap is $63.54M.
When is Annovis Bio’s upcoming earnings report date?
Annovis Bio’s upcoming earnings report date is May 19, 2026 which is in 19 days.
How were Annovis Bio’s earnings last quarter?
Annovis Bio released its earnings results on Mar 16, 2026. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.308 by -$0.082.
Is Annovis Bio overvalued?
According to Wall Street analysts Annovis Bio’s price is currently Undervalued.
Does Annovis Bio pay dividends?
Annovis Bio does not currently pay dividends.
What is Annovis Bio’s EPS estimate?
Annovis Bio’s EPS estimate is -0.4.
How many shares outstanding does Annovis Bio have?
Annovis Bio has 34,532,394 shares outstanding.
What happened to Annovis Bio’s price movement after its last earnings report?
Annovis Bio reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.308. Following the earnings report the stock price went up 12.302%.
Which hedge fund is a major shareholder of Annovis Bio?
Currently, no hedge funds are holding shares in ANVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (568.45% Upside)
$12.50 (568.45% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
53.27%
12-Months-Change
Fundamentals
Return on Equity
-159.43%
Trailing 12-Months
Asset Growth
51.39%
Trailing 12-Months
Company Description
Annovis Bio
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
ANVS Stock 12 Month Forecast
Average Price Target
$12.50
▲(568.45% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―
Ownership Overview
13.75% Insiders
2.87% Mutual Funds
0.29% Other Institutional Investors
80.60% Public Companies and
Individual Investors